Work

Clinical and demographic characteristics of patients with advanced HR+/HER2- breast cancer receiving ribociclib combined with endocrine therapy or combination chemotherapy in Russian clinical practice: second interim analysis of the ValerEE study data

Year: 2026
Type: article
Abstract: This article presents the results of the second interim analysis of data from the ValerEE study. The analysis examined a population of patients with advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer receiving either ribociclib combined with endocrine therapy (ET) or combination chemotherapy (CT) as first-line treatment in a real-world clinical setting in Russia. The study enrolled 100 % of the planned number of participants (N=333; 188 in the ribociclib plus ET group and 145 in the combination CT group). The groups were balanced regarding age (mean: 59.2 years), body mass index (mean: 27.7), menopausal status (75.7 % postmenopausal), and gender. Statistically significant differences between the groups were identified: the ribociclib plus ET group showed a higher proportion of patients with an ECOG performance status of 0 (20.7 % vs. 9.7 %, p=0.0208) and higher mean expression levels of estrogen receptors (7.4 vs. 6.9, p<0.001) and progesterone receptors (6.2 vs. 4.9, p<0.001); HER2-low status was also more frequent (38.8 % vs. 31.1 %, p=0.0344). Metastatic disease, including locoregional metastases, was more common in the chemotherapy group. The findings indicate that, in standard clinical practice in the Russian Federation, the selection of patients with HR+/HER2- recurrent/metastatic breast cancer for first-line therapy is based on clinical and biological characteristics. These differences must be taken into account when interpreting the comparative efficacy of these approaches.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7235857351
FWCI:
Cites: 17
Cited by:
Related to: 10